Curis up 4% on emavusertib data in myelodysplastic syndrome

Hailshadow/iStock via Getty Images Curis ( NASDAQ: CRIS ) is up 4% Tuesday after releasing an abstract containing data on emavusertib in myelodysplastic syndrome. Results on 14 patients with higher-risk MDS who received fewer than 3 lines of prior treatment given emavusertib 300mg twice daily showed four.